



## Correction

# Correction to: Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays

Boris Gorovits,<sup>1,8</sup> Michele Fiscella,<sup>2</sup> Mike Havert,<sup>3</sup> Eugen Koren,<sup>4</sup> Brian Long,<sup>5</sup>  
Mark Milton,<sup>6</sup> and Shobha Purushothama<sup>7</sup>

### Correction to: AAPS J

<https://doi.org/10.1208/s12248-019-0403-1>

The first author's name was published incorrectly as "Gorovits Boris". The correct name is "Boris Gorovits".

There are also several errors in the co-author affiliations. The correct affiliations are below.

Boris Gorovits<sup>1</sup>, Michele Fiscella<sup>2</sup>, Mike Havert<sup>3</sup>, Eugen Koren<sup>4</sup>, Brian Long<sup>5</sup>, Mark Milton<sup>6</sup>, Shobha Purushothama<sup>7</sup>

<sup>1</sup>Pfizer Inc. MA, USA

<sup>2</sup>REGENXBIO Inc., MD, USA

<sup>3</sup>bluebird bio, MA, USA

<sup>4</sup>Precision for Medicine, Inc. CA, USA

<sup>5</sup>BioMarin Pharmaceutical Inc, CA, USA

<sup>6</sup>Novartis Institutes for BioMedical Research, Inc., MA, USA

<sup>7</sup>Alzheimer's Drug Discovery Foundation, USA

In addition, incorrect spacing occurred on the PDF between words on page 23, in the Acknowledgements section.

### ACKNOWLEDGMENTS

Manuscript authors worked as part of the American Association of Pharmaceutical Scientists community and are sincerely grateful to the entire AAPS organization for the support and opportunities provided.

**Glossary** AAV adeno-associated virus

AAV - binding (total) antibodies (Tab) immunoglobulins able to specifically bind to AAV capsid protein epitopes. These antibodies may be neutralizing or non-neutralizing  
AAV neutralizing antibodies (NAb) - immunoglobulins able to specifically bind to AAV capsid protein epitopes and inhibit one or more critical steps involved in AAV infectivity and cell transduction

Companion diagnostic (CDx) - an in vitro test method which provides information that is essential for the safe and effective use of a corresponding drug or biologic product

Gene therapy (GTx) - a technique that uses genes, or genetic modification, to treat or prevent disease

Transgene - a gene that is transferred due to GTx treatment  
Transgene expression of mRNA or protein

Viral vector - viral based tools used to deliver genetical material to cells

The original article has been corrected.

The online version of the original article can be found at <https://doi.org/10.1208/s12248-019-0403-1>

<sup>1</sup> Pfizer Inc., Andover, MA, USA.

<sup>2</sup> REGENXBIO Inc., Rockville, MD, USA.

<sup>3</sup> bluebird bio, Cambridge, MA, USA.

<sup>4</sup> Precision for Medicine, Inc., Costa Mesa, CA, USA.

<sup>5</sup> BioMarin Pharmaceutical Inc, Novato, CA, USA.

<sup>6</sup> Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA.

<sup>7</sup> Alzheimer's Drug Discovery Foundation, New York, NY, USA.

<sup>8</sup> To whom correspondence should be addressed. (e-mail: Boris.Gorovits@pfizer.com)